Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patriot Act and PSE

This article was originally published in The Tan Sheet

Executive Summary

Provisions requiring behind-the-counter placement of products containing pseudoephedrine have been added to the final version of the conference report for the Patriot Act reauthorization package. The report was filed Dec. 8 and will be considered by the House and Senate during the week of Dec. 12, House Judiciary Committee Chairman James Sensenbrenner (R-Wis.), announces. The provision for BTC sale was first added to the draft version of the conference report in November (1"The Tan Sheet" Nov. 28, 2005, p. 3). Also added at that time were essentially all elements of the Talent/Feinstein Combat Meth Act (S 103), except for the provision requiring Schedule V status for pseudoephedrine. The conference report's final version contains a new pseudoephedrine sales limit of 9 g/30 days...

You may also be interested in...

Anti-Meth Draft Places PSE Behind Counter, Lacks Schedule V Language

Current draft report language in the Patriot Act places all pseudoephedrine products behind the counter but does not contain a Schedule V provision, according to the Consumer Healthcare Products Association

Exec Chat: How Edwards Lifesciences Deploys AI, Remote Monitoring To Help Doctors Make Life-Critical Decisions

Edwards Lifesciences’ head of critical care expects that “smart recovery” AI-driven products will grow the fastest in its critical care unit, which is expected to reach $800m in total revenues for 2021.

Cara Placing Korsuva Hopes On Oral Formulation, Broad Pruritis Label

I.V. Korsuva now has an August FDA action date, which partner Vifor would commercialize in the ESRD dialysis setting while Cara works toward a broad anti-pruritus label for its oral tablet formulation.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts